CSL300 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 14, 2026

The clinical evidence base for CSL300 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Atherosclerosis. Most recent publication: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial., Nat Med, 2024.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Chertow GM, Chang AM, Felker GM, et al. · Nat Med · 2024
PubMed: PMID 38796655 · NCT05485961 (POSIBIL6ESKD) · Atherosclerosis

Publications by year

2024–2024: 1 publications.

2024

Publications by indication

Atherosclerosis (1)

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Nat Med · 2024 · PMID 38796655 · NCT05485961

Publications by journal

Nat Med1 paper

All CSL300 publications (1)

2024 (1 paper)

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Chertow GM, Chang AM, Felker GM, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38796655 · NCT05485961 (POSIBIL6ESKD) · Atherosclerosis

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Thu, 14 May 2026 22:39:22 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).